On September 10, 2019 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, reported that Richard Godfrey, BergenBio’s chief executive officer, will present at the H.C. Wainwright 21st Annual Global Life Sciences Conference today, September 10, 2019 (Press release, BerGenBio, SEP 10, 2019, View Source [SID1234539426]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, September 10, 2019
Time: 5.15pm CEST
Location: Lotte New York Palace Hotel, New York
The presentation slides will be available on www.bergenbio.com in the investor section at the time of the presentation.